Completed OBSERVATIONAL NCT04799873

Alpha-1-Antitrypsin-Deficiency in COVID-19 (CORSAAR-AAT)

Individual Treatment of COVID-19 by Application of Alpha-1-antitrypsin

Sponsor: Universität des Saarlandes

Conditions Covid19

Updated 5 times since 2021 Last updated: May 21, 2025 Started: Apr 8, 2020 Primary completion: Dec 1, 2020 Completion: Dec 1, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04799873, this observational or N/A phase trial focuses on Covid19 and remains completed. Sponsored by Universität des Saarlandes, it has been updated 5 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Jun 2025 — Present [monthly]

Completed
Sep 2024 — Jun 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2021 — Jul 2024 [monthly]

Completed
Apr 2021 — Dec 2021 [monthly]

Completed

First recorded

Apr 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Universität des Saarlandes

Data source: Universität des Saarlandes

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Homburg, Germany